Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 27

Results For "ABI"

3263 News Found

Teva unveils promising SOLARIS resultsfor Olanzapine LAI
Clinical Trials | September 23, 2025

Teva unveils promising SOLARIS resultsfor Olanzapine LAI

No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks


Akums demonstrates clinical versatility of Lacosamide in epilepsy care
Clinical Trials | September 23, 2025

Akums demonstrates clinical versatility of Lacosamide in epilepsy care

Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.


AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps
News | September 23, 2025

AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps

Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent


Fermenta to sell environmental solutions business to its subsidiary
Sustainability | September 21, 2025

Fermenta to sell environmental solutions business to its subsidiary

The entity will undertake the installation, operation, and maintenance of sewage treatment plants


FDA approves Merck's Keytruda injection for cancer therapy
Drug Approval | September 21, 2025

FDA approves Merck's Keytruda injection for cancer therapy

Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute


Datavant partners with Indegene to power clinical trial recruitment
Digitisation | September 21, 2025

Datavant partners with Indegene to power clinical trial recruitment

Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials


Roche to acquire 89bio in $3.5B deal
News | September 20, 2025

Roche to acquire 89bio in $3.5B deal

Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins